A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
- CpG has the potential to stimulate the immune system
- this study will evaluate the safety of CpG given sub-q or IV
- purpose is to measure biological changes in CLL cells after receiving CpG
Phase:
Phase 1
Details
Lead Sponsor:
University of Iowa
Collaborators:
Mayo Clinic National Cancer Institute (NCI) Pfizer